NIH-funded research U01 cooperative agreement

Developing a vaccine to prevent syphilis using outer membrane proteins.

Official title: A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum

Funded at Duke University · NIH-11077819 · Data updated 2026-11-12

This study is working on a new vaccine to help prevent syphilis by focusing on certain proteins from the bacteria that cause it, and if successful, it could offer protection for people at risk of this infection.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionDuke University
NIH-funded
Lab location1 site (Durham, United States)
Project startApril 22, 2024
Project endMarch 31, 2029
Funding year2025
Award (this year)$2,276,756
NIH project number5U01AI182179-02
Project IDNIH-11077819 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for participation or benefit from this research would include individuals at high risk for syphilis infection, such as those in certain geographic areas or with specific behavioral risk factors.

Less likely to help

Patients who are already infected with syphilis or those who do not have risk factors for syphilis may not receive benefit from this research.

What this research studies

This research aims to create a vaccine against syphilis by targeting specific proteins found in the outer membrane of the Treponema pallidum bacteria. The approach combines advanced techniques in bioinformatics and biophysics to identify and characterize these proteins, which are believed to be crucial for eliciting a protective immune response. The project will involve preclinical studies in animal models to test the effectiveness of the vaccine before moving to human trials. Patients may benefit from this research if the vaccine proves effective in preventing syphilis infections.

Why it matters

Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the incidence of syphilis and its associated health complications.

How similar studies have gone: Other research has shown promise in developing vaccines targeting similar bacterial outer membrane proteins, indicating a potential for success in this approach.

Where this research is happening

  • Duke University
    Durham, United States
    Active

Researchers

  • Principal investigator: Moody, Michael Anthony — Duke University
  • Study coordinator: Moody, Michael Anthony

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.